Clinical trial NCT03993535 - References

Obsessive-Compulsive Disorder — Predicting Treatment Response in Patients With OCD

Citation(s)

•   Alarcon RD, Libb JW, Spitler D
  A predictive study of obsessive-compulsive disorder response to clomipramine. J Clin Psychopharmacol. 1993 Jun;13(3):210-3.
•   Atmaca M, Mermi O, Yildirim H, Gurok MG
  Orbito-frontal cortex and thalamus volumes in obsessive-compulsive disorder before and after pharmacotherapy. Brain Imaging Behav. 2016 Sep;10(3):669-74. doi: 10.1007/s11682-015-9426-0.
•   Baer L, Jenike MA, Black DW, Treece C, Rosenfeld R, Greist J
  Effect of axis II diagnoses on treatment outcome with clomipramine in 55 patients with obsessive-compulsive disorder. Arch Gen Psychiatry. 1992 Nov;49(11):862-6. doi: 10.1001/archpsyc.1992.01820110026003.
•   Bhikram TP, Farb NA, Ravindran LN, Papadopoulos YG, Conn DK, Pollock BG, Ravindran AV
  The Effect of Intravenous Citalopram on the Neural Substrates of Obsessive-Compulsive Disorder. J Neuropsychiatry Clin Neurosci. 2016 Summer;28(3):243-7. doi: 10.1176/appi.neuropsych.15090213. Epub 2016 Mar 28.
•   Cannistraro PA, Makris N, Howard JD, Wedig MM, Hodge SM, Wilhelm S, Kennedy DN, Rauch SL
  A diffusion tensor imaging study of white matter in obsessive-compulsive disorder. Depress Anxiety. 2007;24(6):440-6. doi: 10.1002/da.20246.
•   Carrasco JL, Hollander E, Schneier FR, Liebowitz MR
  Treatment outcome of obsessive compulsive disorder with comorbid social phobia. J Clin Psychiatry. 1992 Nov;53(11):387-91.
•   D'Alcante CC, Diniz JB, Fossaluza V, Batistuzzo MC, Lopes AC, Shavitt RG, Deckersbach T, Malloy-Diniz L, Miguel EC, Hoexter MQ
  Neuropsychological predictors of response to randomized treatment in obsessive-compulsive disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2012 Dec 3;39(2):310-7. doi: 10.1016/j.pnpbp.2012.07.002. Epub 2012 Jul 10.
•   Erzegovesi S, Cavallini MC, Cavedini P, Diaferia G, Locatelli M, Bellodi L
  Clinical predictors of drug response in obsessive-compulsive disorder. J Clin Psychopharmacol. 2001 Oct;21(5):488-92. doi: 10.1097/00004714-200110000-00006.
•   Flessner CA, Allgair A, Garcia A, Freeman J, Sapyta J, Franklin ME, Foa E, March J
  The impact of neuropsychological functioning on treatment outcome in pediatric obsessive-compulsive disorder. Depress Anxiety. 2010 Apr;27(4):365-71. doi: 10.1002/da.20626.
•   Garibotto V, Scifo P, Gorini A, Alonso CR, Brambati S, Bellodi L, Perani D
  Disorganization of anatomical connectivity in obsessive compulsive disorder: a multi-parameter diffusion tensor imaging study in a subpopulation of patients. Neurobiol Dis. 2010 Feb;37(2):468-76. doi: 10.1016/j.nbd.2009.11.003. Epub 2009 Nov 11.
•   Hazari N, Narayanaswamy JC, Arumugham SS
  Predictors of response to serotonin reuptake inhibitors in obsessive-compulsive disorder. Expert Rev Neurother. 2016 Oct;16(10):1175-91. doi: 10.1080/14737175.2016.1199960. Epub 2016 Jun 30.
•   Jakubovski E, Diniz JB, Valerio C, Fossaluza V, Belotto-Silva C, Gorenstein C, Miguel E, Shavitt RG
  Clinical predictors of long-term outcome in obsessive-compulsive disorder. Depress Anxiety. 2013 Aug;30(8):763-72. doi: 10.1002/da.22013. Epub 2012 Oct 25.
•   Jenike MA, Baer L, Minichiello WE, Schwartz CE, Carey RJ Jr
  Concomitant obsessive-compulsive disorder and schizotypal personality disorder. Am J Psychiatry. 1986 Apr;143(4):530-2. doi: 10.1176/ajp.143.4.530.
•   Mataix-Cols D, Fernandez de la Cruz L, Nordsletten AE, Lenhard F, Isomura K, Simpson HB
  Towards an international expert consensus for defining treatment response, remission, recovery and relapse in obsessive-compulsive disorder. World Psychiatry. 2016 Feb;15(1):80-1. doi: 10.1002/wps.20299. No abstract available.
•   Mataix-Cols D, Rauch SL, Manzo PA, Jenike MA, Baer L
  Use of factor-analyzed symptom dimensions to predict outcome with serotonin reuptake inhibitors and placebo in the treatment of obsessive-compulsive disorder. Am J Psychiatry. 1999 Sep;156(9):1409-16. doi: 10.1176/ajp.156.9.1409.
•   Nakao T, Nakagawa A, Yoshiura T, Nakatani E, Nabeyama M, Yoshizato C, Kudoh A, Tada K, Yoshioka K, Kawamoto M, Togao O, Kanba S
  Brain activation of patients with obsessive-compulsive disorder during neuropsychological and symptom provocation tasks before and after symptom improvement: a functional magnetic resonance imaging study. Biol Psychiatry. 2005 Apr 15;57(8):901-10. doi: 10.1016/j.biopsych.2004.12.039.
•   Ravizza L, Barzega G, Bellino S, Bogetto F, Maina G
  Predictors of drug treatment response in obsessive-compulsive disorder. J Clin Psychiatry. 1995 Aug;56(8):368-73.
•   Sanematsu H, Nakao T, Yoshiura T, Nabeyama M, Togao O, Tomita M, Masuda Y, Nakatani E, Nakagawa A, Kanba S
  Predictors of treatment response to fluvoxamine in obsessive-compulsive disorder: an fMRI study. J Psychiatr Res. 2010 Mar;44(4):193-200. doi: 10.1016/j.jpsychires.2009.08.007. Epub 2009 Sep 15.
•   Shavitt RG, Valerio C, Fossaluza V, da Silva EM, Cordeiro Q, Diniz JB, Belotto-Silva C, Cordioli AV, Mari J, Miguel EC
  The impact of trauma and post-traumatic stress disorder on the treatment response of patients with obsessive-compulsive disorder. Eur Arch Psychiatry Clin Neurosci. 2010 Mar;260(2):91-9. doi: 10.1007/s00406-009-0015-3.
•   Shin NY, Lee TY, Kim E, Kwon JS
  Cognitive functioning in obsessive-compulsive disorder: a meta-analysis. Psychol Med. 2014 Apr;44(6):1121-30. doi: 10.1017/S0033291713001803. Epub 2013 Jul 19.
•   Stein DJ, Montgomery SA, Kasper S, Tanghoj P
  Predictors of response to pharmacotherapy with citalopram in obsessive-compulsive disorder. Int Clin Psychopharmacol. 2001 Nov;16(6):357-61. doi: 10.1097/00004850-200111000-00007.
•   Szeszko PR, Ardekani BA, Ashtari M, Malhotra AK, Robinson DG, Bilder RM, Lim KO
  White matter abnormalities in obsessive-compulsive disorder: a diffusion tensor imaging study. Arch Gen Psychiatry. 2005 Jul;62(7):782-90. doi: 10.1001/archpsyc.62.7.782.
•   Szeszko PR, MacMillan S, McMeniman M, Lorch E, Madden R, Ivey J, Banerjee SP, Moore GJ, Rosenberg DR
  Amygdala volume reductions in pediatric patients with obsessive-compulsive disorder treated with paroxetine: preliminary findings. Neuropsychopharmacology. 2004 Apr;29(4):826-32. doi: 10.1038/sj.npp.1300399.
•   Yoo SY, Jang JH, Shin YW, Kim DJ, Park HJ, Moon WJ, Chung EC, Lee JM, Kim IY, Kim SI, Kwon JS
  White matter abnormalities in drug-naive patients with obsessive-compulsive disorder: a diffusion tensor study before and after citalopram treatment. Acta Psychiatr Scand. 2007 Sep;116(3):211-9. doi: 10.1111/j.1600-0447.2007.01046.x.
•   Yun JY, Jang JH, Kim SN, Jung WH, Kwon JS
  Neural Correlates of Response to Pharmacotherapy in Obsessive-Compulsive Disorder: Individualized Cortical Morphology-Based Structural Covariance. Prog Neuropsychopharmacol Biol Psychiatry. 2015 Dec 3;63:126-33. doi: 10.1016/j.pnpbp.2015.06.009. Epub 2015 Jun 24.

Clinical, Neurocognitive and Neuroimaging Variables Associated With Response to Treatment in Patients With OCD

Details for clinical trial NCT03993535